Want to see LRMR full AI Analyst Report?
LRMR Stock Chart & Stats
$4.00
-$0.11(-2.75%)
At close: 4:00 PM EDT
$4.00
-$0.11(-2.75%)
Day’s Range― - ―
52-Week Range$2.72 - $6.42
Previous CloseN/A
Volume458.18K
Average Volume (3M)2.47M
Market Cap
$396.83M
Enterprise Value$209.55
Total Cash (Recent Filing)$200.38M
Total Debt (Recent Filing)$3.78M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Aug 06, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.10
Shares Outstanding103,882,935
10 Day Avg. Volume1,373,940
30 Day Avg. Volume2,472,096
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.50Price Target Upside212.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Debt ProfileVery low reported debt (~$3.8M; debt-to-equity ~0.02) reduces refinancing and interest-rate risk, giving management flexibility to prioritize R&D. Over a multi-month horizon this conservative leverage profile lowers the chance that development programs are constrained by creditor covenants or high interest costs.
Regulatory Progress: Rolling BLA And Surrogate AlignmentSubmission of a rolling BLA and explicit FDA alignment on a surrogate biomarker materially lowers regulatory uncertainty versus earlier stages. This structural advancement shortens the pathway to potential approval and supports planning for confirmatory trials, partnerships, and commercialization if the surrogate is accepted.
Supportive Biomarker And Cross-species Efficacy DataSustained biomarker increases and directional functional improvements, backed by peer-reviewed cross-species data, strengthen biological plausibility and surrogate credibility. Over months this raises the likelihood a confirmatory trial will show benefit and supports payer/regulatory confidence for a rare disease first-in-class therapy.
Bears Say
Pre-revenue With Materially Larger LossesOperating without product revenue and with a TTM net loss around -$166M constrains financial self-sufficiency. Over a multi-month horizon this negative earnings profile increases dependency on external capital, reduces flexibility for commercial investments, and heightens stakeholder sensitivity to trial and regulatory outcomes.
Accelerating Cash Burn And Limited RunwayCash burn has accelerated materially (TTM operating cash flow ~-131.3M) and available liquidity was noted as runway only into Q2 2027. Structurally, this forces financing or partnership decisions within months, increasing execution risk and the probability of dilutive capital raises that affect long-term shareholder value.
Authorized Share Expansion Increases Dilution RiskDoubling authorized shares provides clear flexibility to raise capital or pursue transactions, but it also materially raises the ceiling for dilution. Over the medium term this structurally increases the likelihood of equity issuance to fund development, potentially diluting existing holders and complicating governance incentives.
Larimar Therapeutics News
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $2.71 and its highest was $6.42 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is $396.83M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on May 14, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.535 by $0.225.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.38.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 103,882,935 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.535. Following the earnings report the stock price went down -5.122%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LRMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Larimar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.50 (212.50% Upside)
$12.50 (212.50% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 8.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $166.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
22.53%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
LRMR Stock 12 Month Forecast
Average Price Target
$12.50
▲(212.50% Upside)
Technical Analysis
Omeros
―
Vanda
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
35.99% Insiders
5.48% Mutual Funds
0.55% Other Institutional Investors
49.55% Public Companies and Individual Investors